KalVista Pharmaceuticals, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

KalVista Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $12.69 million for the year ending 2020.

  • KalVista Pharmaceuticals, Inc. showed a decrease of -21.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2019 to 2020.
  • This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 7, 2022.
  • XBRL data for this metric is available from 2017 to 2020 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2017 to 2020), KalVista Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 743.8%.
  • Historical annual values: Fiscal year 2020: $12.69 million | Fiscal year 2019: $16.13 million | Fiscal year 2018: $8.39 million | Fiscal year 2017: $1.50 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: